A pH-sensitive silica nanoparticles for colon-specific delivery and controlled release of catechin: Optimization of loading efficiency and in vitro release kinetics

Kassem, Abdulsalam M.; Almukainzi, May; Faris, Tarek M.; Ibrahim, Ahmed H.; Anwar, Walid; Elbahwy, Ibrahim A.; El-Gamal, Farid R.; Zidan, Mohamed F.; Akl, Mohamed A.; Abd-ElGawad, Ahmed M.; Elshamy, Abdelsamed I.; Elmowafy, Mohammed

doi:10.1016/j.ejps.2023.106652

Cited by 2 publications

(1 citation statement)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ES100 and ERS100 (a time-dependent polymer) were extensively used in targeted oral drug delivery systems; they were used singularly or coupled together [ 110 , 111 ] and even in the form of microspheres [ 112 ] and showed an effective response to pH changes along the gastrointestinal tract. They were exploited for IBD [ 113 ], IBS [ 114 , 115 , 116 ], and colon cancer treatments [ 117 ]. Eudragits can be coated with biopolymers such as chitosan to increase the adhesion to intestinal mucosa.…”

Section: Resultsmentioning

confidence: 99%

Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers

Garbati,

Picco,

Magrassi

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

The intestine is essential for the modulation of nutrient absorption and the removal of waste. Gut pathologies, such as cancer, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and celiac disease, which extensively impact gut functions, are thus critical for human health. Targeted drug delivery is essential to tackle these diseases, improve therapy efficacy, and minimize side effects. Recent strategies have taken advantage of both active and passive nanocarriers, which are designed to protect the drug until it reaches the correct delivery site and to modulate drug release via the use of different physical–chemical strategies. In this systematic review, we present a literature overview of the different nanocarriers used for drug delivery in a set of chronic intestinal pathologies, highlighting the rationale behind the controlled release of intestinal therapies. The overall aim is to provide the reader with useful information on the current approaches for gut targeting in novel therapeutic strategies.

show abstract